ISI Papers With Our Products

Title: mZD7349 peptide-conjugated PLGA nanoparticles directed against VCAM-1 for targeted delivery of simvastatin to restore dysfunctional HUVECs
Journal: Microvascular Research
Author: 1. Akram Vatannejad, Maliheh Paknejad, Mahmood Doosti, 1,2. Fatemeh Imanparast, 3. Mohammad Ali Faramarzi, 4. Behnas Deiham, 5. Farzad Kobarfard, 6,7. Amir Amani
Year: 2017
Address: 1. Department of Medical Biochemistry, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran 2. Department of Laboratory Sciences, Faculty of Khomein Medical Sciences, Arak University of Medical Sciences, Arak, Iran 3. Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran 4. Division of Microbiology, Department of Pathobiology, School of Public Health Tehran University of Medical Sciences, Tehran, Iran 5. Department of Medicinal Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran 6. Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran 7. Medical Biomaterials Research Center (MBRC), Tehran University of Medical Sciences, Tehran, Iran
Abstract: Endothelial dysfunction is initial and critical step of atherosclerosis. Impaired bioavailability of endothelial nitric oxide synthase (eNOS) is one of the main reasons of endothelial dysfunction. Improving bioavailability of eNOS by increasing its expression or activity using statins is an effective therapeutic strategy in restoring endothelial dysfunction. In this study, simvastatin (SIM) as a poorlywater-soluble drugwas loaded in poly (lactic-co-glycolic acid) (PLGA) nanoparticles (SIM-PLGA-NPs). NPs were then conjugated with mZD7349 peptide (mZD7349-SIM-PLGA-NPs) and directed against vascular cell adhesion molecule 1 (VCAM-1). In vitro evaluation of the NPs for targeted delivery of SIM was performed on activated Human Umbilical Cord Vascular Endothelial Cells (HUVECs) by tumor necrosis factor alpha (TNF-α). Effect of mZD7349-SIM-PLGA-NPs and SIM-PLGA-NPs was compared on eNOS phosphorylation (ser-1177). Results ofwestern blot showed SIMpost-treatment increased significantly phosphor-eNOS (Ser1177) expression but no total eNOS expression. The study showed that mZD7349-SIM-PLGA-NPs have particle size, zeta potential value, polydispersity index (PDI) and encapsulation efficacy % of 233±18 nm,−9.6±1.1 mV, 0.59±0.066 and 69 ± 17.3%, respectively. Also phosphor-eNOS (Ser1177) expression in activated HUVECs treated with mZD7349-SIM-PLGA-NPs was significantly (p b 0.05) better than treated cells with SIM-PLGA-NPs. The results suggest that mZD7349-SIM-PLGA-NPs may be usable as an appropriate drug carrier for restoring endothelial dysfunction.
Keywords: Poly (DL-lactic-co-glycolic acid) nanoparticles Simvastatin mZD7349 peptide Endothelium Vascular cell-adhesion molecule-1 Phospho-eNOS (Ser1177) HUVECs
Application: Drug Delivery
Product Model 1: Electroris
Product Model 2:
URL:"" & "/science/article/pii/S0026286216301194"#